`
`Page 1 of 27 PagelD #: 1 Case 1:20-cv-01730-UNA Document 1 Filed 12/21/20
`
`
`
`IN THE UNITED STATES DISTRICT COURT
`
`FOR THE DISTRICT OF DELAWARE
`
`
`
`Ravgen, Inc.,
`
`Plaintiff, Civil Action No.
`
`V.
`
`
`
`Myriad Genetics, Inc., and Myriad Women's
`
`
`Health, Inc.,
`
`JURY TRIAL DEMANDED
`
`Defendants.
`
`COMPLAINT FOR PATENT INFRINGEMENT
`
`
`
`
`
`
`
`
`
`
`
`Plaintiff Ravgen, Inc. ("Ravgen"), for its Complaint against Defendants Myriad Genetics,
`
`
`
`
`
`
`
`Inc. ("Myriad") and Myriad Women's Health, Inc. ("MWH") (collectively "Defendants"), hereby
`
`
`
`
`
`alleges as follows:
`
`
`
`NATURE OF THE ACTION
`
`
`
`
`
`1. This is a civil action for infringement of United States Patent Nos. 7,727,720 (the
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`"'720 Patent") and 7,332,277 (the "'277 Patent") ( collectively the "Patents-in-Suit"), arising under
`
`
`
`
`
`the Patent Laws of the United States, 35 U.S.C. §§ 271 et seq.
`
`
`
`
`
`THE PARTIES
`
`
`
`business atwith its principal place of corporation 2. Plaintiff Ravgen is a Delaware
`
`
`
`
`
`
`
`
`
`
`
`
`
`9241 Rumsey Rd., Columbia, MD 21045. Ravgen is a pioneering diagnostics company that
`
`
`
`focuses on non-invasive prenatal testing.
`
`
`Ravgen has spent millions of dollars researching and
`
`
`
`developing novel methods for the detection of cell-free DNA to replace conventional, invasive
`
`
`
`
`
`
`
`
`
`
`
`
`
`procedures. Ravgen's innovative cell-free DNA technology has various applications, including
`
`
`
`
`
`
`
`
`
`IPR2021-01577
`
`
`Streck, Inc. v. Ravgen, Inc.
`
`
`
`Ravgen, lnc.'s Exhibit 2183
`Ex. 2183, Page 1
`
`

`

`Case 1:20-cv-01730-UNA Document 1 Filed 12/21/20 Page 2 of 27 PagelD #: 2
`
`non-invasive prenatal and other genetic testing. Those efforts have resulted in the issuance of
`
`several patents, including the Patents-in-Suit.
`
`3.
`
`Defendant Myriad is a company organized and existing under the laws of the State
`
`of Delaware, with its principal place of business at 320 Wakara Way, Salt Lake City, Utah 84108.
`
`(Ex. 7 (Myriad Genetics Form 10-K, June 30, 2020) at 1.) Myriad has appointed The Corporation
`
`Trust Company, Corporation Trust Center 1209 Orange Street, Wilmington, Delaware 19801 as
`
`its agent for service of process. (Ex. 8 (State of Delaware Entity Status for Myriad Genetics, Inc.).)
`
`4.
`
`Defendant MWH is a company organized and existing under the laws of the State
`
`of Delaware, with its principal place of business at 180 Kimball Way, South San Francisco,
`
`California 94080. (Ex. 9 (https:Hmyriadwomenshealth.com/about-us/); Ex. 7 (Myriad Genetics
`
`Form 10-K, June 30, 2020) at 103.) MWH has appointed The Corporation Trust Company,
`
`Corporation Trust Center 1209 Orange Street, Wilmington, Delaware 19801 as its agent for service
`
`of process. (Ex. 10 (State of Delaware Entity Status for Myriad Women's Health, Inc.).) MWH
`
`is a wholly-owned subsidiary of Myriad Genetics. (Ex. 7 (Myriad Genetics Form 10-K, June 30,
`
`2020) at 103.)
`
`5.
`
`Defendants, themselves and/or through their subsidiaries and affiliates, make, use,
`
`and commercialize noninvasive prenatal tests that utilize circulating cell-free DNA (cfDNA) to
`
`screen for and detect genetic abnormalities, such as aneuploidy of chromosomes, marketed under
`
`the tradenames "Prequel," "Prelude," and "Informed."
`
`6.
`
`Defendants have offered and marketed tests under the Prequel, Prelude, and
`
`Informed tradenames throughout the United States, including without limitation through the
`
`website,
`
`www.myriadwomenshealth.com.
`
`(See
`
`generally
`
`Ex.
`
`11
`
`(https:Hmyriadwomenshealth.com/provider-prequel/).)
`
`2
`
`Ex. 2183, Page 2
`
`

`

`Case 1:20-cv-01730-UNA Document 1 Filed 12/21/20 Page 3 of 27 PagelD #: 3
`
`JURISDICTION AND VENUE
`
`Ravgen incorporates by reference paragraphs 1-6.
`
`This action arises under the patent laws of the United States, including 35 U.S.C.
`
`7.
`
`8.
`
`§S 271 etseq. The jurisdiction of this Court over the subject matter of this action is proper under
`
`28 U.S.C. §S 1331 and 1338(a).
`
`9.
`
`Venue is proper in this District pursuant to 28 U.S.C. §§ 1391(b), (c), and 1400(b).
`
`Defendants are entities organized under the laws of Delaware and reside in Delaware for purposes
`
`of venue under 28 U.S.C. § 1400(b). Defendants conduct business in Delaware, at least by offering
`
`for sale and selling products and services through their websites, which are accessible in Delaware.
`
`Defendants have also committed and continue to commit acts of infringement in this District.
`
`10.
`
`This Court has personal jurisdiction over Defendants because Defendants conduct
`
`business in Delaware by at least offering for sale or selling products and services through their
`
`websites, which are accessible in Delaware, and because infringement has occurred and continues
`
`to occur in Delaware.
`
`11.
`
`Personal jurisdiction also exists over Defendants because they are entities
`
`organized under the laws of Delaware.
`
`BACKGROUND OF THE INVENTION
`
`12.
`
`Dr. Ravinder S. Dhallan is the founder of Ravgen, Inc. and the inventor of several
`
`patents in the field of detection of genetic disorders, including chromosomal abnormalities and
`
`mutations. Ravgen's mission is to provide state of the art genetic testing that will enrich the lives
`
`of its patients. For example, through the use of its novel techniques in non-invasive prenatal
`
`diagnostic testing, Ravgen gives patients the knowledge they need to prepare for their pregnancies
`
`and treat diseases at an early stage.
`
`3
`
`Ex. 2183, Page 3
`
`

`

`Case 1:20-cv-01730-UNA Document 1 Filed 12/21/20 Page 4 of 27 PagelD #: 4
`
`13.
`
`Prior to founding Ravgen, Dr. Dhallan was a board-certified emergency room
`
`physician. Between starting medical school at Johns Hopkins University and shortly after his
`
`residency at Mass General (Harvard University School of Medicine), Dr. Dhallan and his wife
`
`suffered three miscarriages. At that time, the prenatal diagnostic testing procedures available
`
`included (a) non-invasive techniques with low sensitivity and specificity, and (b) tests with higher
`
`sensitivity and specificity that were highly invasive and therefore associated with a risk for loss of
`
`pregnancy. After discovering the limitations on the available techniques for prenatal testing, Dr.
`
`Dhallan made it his mission to invent an improved prenatal diagnostic exam—one that was both
`
`non-invasive and accurate. In September of 2000, Dr. Dhallan founded Ravgen (which stands for
`
`"Rapid Analysis of Variations in the GENome") to pursue that goal.
`
`14.
`
`Prior to Ravgen's inventions, scientists had recognized the need for a genetic testing
`
`technique that used "cell-free" or "free" fetal DNA circulating in maternal blood. A technique that
`
`relied on circulating free fetal DNA would require only a simple blood draw from the mother and
`
`would therefore be an improvement over invasive diagnostic tests.
`
`15.
`
`However, at that time, the use of free fetal DNA for detecting chromosomal
`
`abnormalities was limited by the low percentage of free fetal DNA that could be recovered from a
`
`sample of maternal blood using existing techniques. (See, e.g., Ex. 12 (Y.M. Dennis Lo et al.,
`
`Presence f Fetal DNA in Maternal Plasma and Serum, 350 THE LANCET 768-75 (1997),
`
`https://doi.org/10.1016/50140-6736(97)02174-0).) Dr. Dhallan recognized that a method that
`
`could increase the percentage of free fetal DNA relative to the free maternal DNA in a sample was
`
`necessary to the development of an accurate, non-invasive prenatal diagnostic test.
`
`16.
`
`After substantial research, Dr. Dhallan conceived that including an agent that
`
`impedes cell lysis (disruption of the cell membrane) if cells are present during sample collection,
`
`4
`
`Ex. 2183, Page 4
`
`

`

`Case 1:20-cv-01730-UNA Document 1 Filed 12/21/20 Page 5 of 27 PagelD #: 5
`
`shipping, handling, and processing would permit the recovery of a larger percentage of cell-free
`
`fetal DNA (relative to the cell-free maternal DNA in a sample). Dr. Dhallan hypothesized that
`
`this new approach would decrease the amount of maternal cell lysis and therefore lower the amount
`
`of cell-free maternal DNA in the sample, thereby increasing the percentage of cell-free fetal DNA.
`
`He developed a novel method for processing cell-free fetal DNA that involved the addition of an
`
`agent that impedes cell lysis—for example, a membrane stabilizer, a cross-linker, and/or a cell
`
`lysis inhibitor—to maternal blood samples coupled with careful processing protocols. With that
`
`novel method, Dr. Dhallan was able to increase the relative percentage of cell-free fetal DNA in
`
`the processed sample.
`
`17.
`
`Having successfully increased the relative percentage of cell-free fetal DNA
`
`recovered, Dr. Dhallan next addressed the challenge of distinguishing between the cell-free
`
`maternal and cell-free fetal DNA in a sample in order to determine whether a chromosomal
`
`abnormality is present in the fetal DNA. Prior to Ravgen's inventions, known methods for
`
`detecting fetal chromosomal abnormalities were time-consuming and burdensome. Many required
`
`amplification of the entire sequence of a gene, or quantification of the total amount of a particular
`
`gene product in a sample. Dr. Dhallan developed an alternate method that greatly increased the
`
`efficiency of this process by taking advantage of the variation of base sequences among different
`
`individuals (including a mother and fetus) ("alleles") at particular positions ("loci") on
`
`chromosomes. The term "allele" refers to an alternate form of a gene, or a non-coding region of
`
`DNA that occurs at a particular locus on a chromosome. The alleles present at certain loci on
`
`chromosomes (including, for example, "single nucleotide polymorphisms" or "SNPs") vary
`
`between different individuals. At such a locus, a fetus may therefore inherit an allele from its
`
`father that differs from the alleles present at that locus on its mother's chromosome. Dr. Dhallan
`
`5
`
`Ex. 2183, Page 5
`
`

`

`Case 1:20-cv-01730-UNA Document 1 Filed 12/21/20 Page 6 of 27 PagelD #: 6
`
`developed a novel method for quantifying the allelic ratio at such a locus (or loci) of interest in a
`
`sample comprising maternal and fetal cell-free DNA in order to detect whether a fetal
`
`chromosomal abnormality was present in the fetal DNA of the sample, without requiring physical
`
`separation of the fetal from the maternal cell-free DNA.
`
`18.
`
`Dr. Dhallan understood that his breakthroughs laid the foundation for the
`
`development of accurate non-invasive prenatal diagnostic tests. For example, he published a paper
`
`in the Journal f the American Medical Association (JAMA) in 2004, explaining that "the methods
`
`described herein for increasing the percentage of cell-free fetal DNA provide a solid foundation
`
`for the development of a noninvasive prenatal diagnostic test." (Ex. 13 at 1119 (R. Dhallan et al.,
`
`Methods to Increase the Percentage (f Free Fetal D-NA Recoveredfrom the Maternal Circulation,
`
`291 JAMA1114-19(2004),https://doi.org/10.1001/jama.291.9.1114).)
`
`19.
`
`JAMA also ran an editorial alongside Dr. Dhallan's article in 2004, recognizing the
`
`significance of his inventions to applications in prenatal genetic diagnosis and cancer detection
`
`and surveillance:
`
`In this issue of THE JOURNAL, the findings reported in the study
`by Dhallan and colleagues on enhancing recovery of cell-free DNA
`in maternal blood have major clinical implications. Developing a
`reliable, transportable technology for cell-free DNA analysis
`impacts 2 crucial areas—prenatal genetic diagnosis and cancer
`detection and surveillance. In prenatal genetic diagnosis, detecting
`a fetal abnormality without an invasive procedure (or with fewer
`invasive procedures) is a major advantage. Likewise in cancer
`surveillance (eg, in patients with leukemia), monitoring treatment
`without having to perform a bone marrow aspiration for karyotype
`also would be of great benefit.
`
`***
`
`With prospective studies focusing on clinical applications of these
`findings, profound clinical implications could emerge for prenatal
`diagnosis and cancer surveillance.
`
`6
`
`Ex. 2183, Page 6
`
`

`

`Case 1:20-cv-01730-UNA Document 1 Filed 12/21/20 Page 7 of 27 PagelD #: 7
`
`(Ex. 14 at 1135, 1137 (J.L. Simpson & F. Bischoff, Cell-Free Fetal DNA in Maternal Blood.
`
`Evolving
`
`Clinical
`
`Applications,
`
`291
`
`JAMA
`
`1135-37
`
`(2004),
`
`https:Hdol.org/10.1001/jama.291.9. 1135).)
`
`20.
`
`In 2007, Dr. Dhallan published a second journal article in The Lancet that presented
`
`a study showcasing Ravgen's ability to use its novel technology to detect Down's syndrome using
`
`free fetal DNA in a maternal blood sample. (Ex. 15 (R. Dhallan et al., A Non-Invasive Test for
`
`Prenatal Diagnosis Based on Fetal D-NA Present in Maternal Blood. A Preliminary Study, 369
`
`THE LANCET 474-81(2007), https:Hdol.org/10.1016/SO140-6736(07)60115-9).) Dr. Dhallan's
`
`peers at The Lancet also recognized that his innovative test "opens a new era in prenatal screening."
`
`(See Ex. 16 (A. Benachi & J.M. Costa, Non-Invasive Prenatal Diagnosis f Fetal Anenploidies,
`
`369 THE LANCET 440-42 (2007), https://doi.org/10.1016/50140-6736(07)60116-0).)
`
`21.
`
`Dr. Dhallan's publications received worldwide press coverage, from outlets such
`
`as CNN, BBC, and Washington Post. (See Ex. 17 (L. Palmer, A Better Prenatal Test?, CNN
`
`MONEY (Sept.
`
`12,
`
`2007), https:Hmoney.cnn.com/2007/09/07/smbusiness/amnlocentesis
`
`.fsb/index.htm); Ex. 18 (Hcpe for Scfe Prenatal Gene Test, BBC NEWS, Feb 2, 2007,
`
`http://news.bbc.co.uk/2/hi/health/6320273.stm); Ex. 19 (A. Gardner, Experimental Prenatal Test
`
`Helps Spot Birth Defects, WASH. POST (Feb. 2, 2007), https://www.washingtonpost.com/wp-
`
`dyn/content/article/2007/02/02/AR20070202009 14.html).)
`
`22.
`
`The Patents-in-Suit resulted from Dr. Dhallan's years-long research at Ravgen to
`
`develop these innovative new methods for detecting genetic disorders.
`
`PATENTS-IN-SUIT
`
`23.
`
`Ravgen incorporates by reference paragraphs 1-22.
`
`7
`
`Ex. 2183, Page 7
`
`

`

`Case 1:20-cv-01730-UNA Document 1 Filed 12/21/20 Page 8 of 27 PagelD #: 8
`
`24.
`
`The '277 Patent, entitled "Methods For Detection Of Genetic Disorders," was duly
`
`and legally issued by the United States Patent and Trademark Office on February 19, 2008. The
`
`inventor of the patent is Ravinder S. Dhallan, and the patent is assigned to Ravgen. A copy of the
`
`'277 Patent is attached hereto as Exhibit 1.
`
`25.
`
`Ravgen is the exclusive owner of all rights, title, and interest in the '277 Patent, and
`
`has the right to bring this suit to recover damages for any current or past infringement of the '277
`
`Patent. (See Ex. 3.)
`
`26.
`
`The '720 Patent, entitled "Methods For Detection Of Genetic Disorders," was duly
`
`and legally issued by the United States Patent and Trademark Office on June 1, 2010. The inventor
`
`of the patent is Ravinder S. Dhallan, and the patent is assigned to Ravgen. A copy of the '720
`
`Patent is attached hereto as Exhibit 2.
`
`27.
`
`Ravgen is the exclusive owner of all rights, title, and interest in the '720 Patent, and
`
`has the right to bring this suit to recover damages for any current or past infringement of the '720
`
`Patent. (See Ex. 4.)
`
`28.
`
`The '277 Patent is directed to, among other things, novel methods used in the
`
`detection of genetic disorders. For example, claim 81 of the '277 Patent recites:
`
`A method for preparing a sample for analysis comprising isolating
`free fetal nucleic acid from a the sample, wherein said sample
`comprises an agent that inhibits lysis of cells, if cells are present,
`and wherein said agent is selected from the group consisting of
`membrane stabilizer, cross-linker, and cell lysis inhibitor.
`
`29.
`
`The '720 Patent is directed to novel methods for detecting a free nucleic acid in a
`
`sample. For example, claim 1 of the '720 Patent recites:
`
`A method for detecting a free nucleic acid, wherein said method
`comprises: (a) isolating free nucleic acid from a non-cellular
`fraction of a sample, wherein said sample comprises an agent that
`impedes cell lysis, if cells are present, and wherein said agent is
`
`8
`
`Ex. 2183, Page 8
`
`

`

`Case 1:20-cv-01730-UNA Document 1 Filed 12/21/20 Page 9 of 27 PagelD #: 9
`
`selected from the group consisting of membrane stabilizer, cross-
`linker, and cell lysis inhibitor; and (b) detecting the presence or
`absence of the free nucleic acid.
`
`30.
`
`The Patents-in-Suit are directed to unconventional, non-routine techniques for
`
`preparing and analyzing extracellular circulatory DNA, including for the detection of genetic
`
`disorders. The Patents-in-Suit explain that, inter a/ia, the inventions claimed therein overcame
`
`problems in the field—for example, that the low percentage of fetal DNA in maternal plasma
`
`makes using the DNA for genotyping the fetus difficult—with a novel and innovative solution—
`
`the addition of cell lysis inhibitors, cell membrane stabilizers or cross-linkers to the maternal blood
`
`sample, which increase the percentage of cell-free DNA available for detection and analysis:
`
`The percentage of fetal DNA in maternal plasma is between 0.39-
`11.9% (Pertl, and Bianchi, Obstetrics and Gynecology 98: 483-490
`(2001)). The majority of the DNA in the plasma sample is
`maternal, which makes using the DNA for genotyping the fetus
`difficult. However, methods that increase the percentage of fetal
`DNA in the maternal plasma allow the sequence of the fetal DNA
`to be determined, and allow for the detection of genetic disorders
`including mutations, insertions, deletions, and chromosomal
`abnormalities. The addition of cell lysis inhibitors, cell membrane
`stabilizers or cross-linkers to the maternal blood sample can
`increase the relative percentage of fetal DNA. While lysis of both
`maternal and fetal cells is inhibited, the vast majority of cells are
`maternal, and thus by reducing the lysis of maternal cells, there is a
`relative increase in the percentage of free fetal DNA.
`
`(Ex. 1 ('277 Patent) at 32:24-39; Ex. 2 ('720 Patent) at 33:31-46 (emphases added).)
`
`31.
`
`The Patents-in-Suit teach that the benefit of Dr. Dhallan's discovery, an increase in
`
`the relative percentage of cell-free DNA, is realized by performance of the claimed method,
`
`including through the inclusion of an agent that inhibits the lysis of the cells in a sample:
`
`An overall increase in fetal DNA was achieved by reducing the
`maternal cell lysis, and thus, reducing the amount of maternal DNA
`present in the sample. In this example, formaldehyde was used to
`prevent lysis of the cells, however any agent that prevents the lysis
`of cells or increases the structural integrity of the cells can be used.
`
`9
`
`Ex. 2183, Page 9
`
`

`

`Case 1:20-cv-01730-UNA Document 1 Filed 12/21/20 Page 10 of 27 PagelD #: 10
`
`Two or more than two cell lysis inhibitors can be used. The increase
`in fetal DNA in the maternal plasma allows the sequence of the fetal
`DNA to be determined, and provides for the rapid detection of
`abnormal DNA sequences or chromosomal abnormalities including
`but not limited to point mutation, reading frame shift, transition,
`transversion, addition, insertion, deletion, addition-deletion, frame-
`shift, missense, reverse mutation, and microsatellite alteration,
`trisomy,
`monosomy,
`other
`aneuploidies,
`amplification,
`rearrangement, translocation, transversion, deletion, addition,
`amplification, fragment, translocation, and rearrangement.
`
`(Ex. 1 ('277 Patent) at 91:44-60; Ex. 2 ('720 Patent) at 92:10-26.)
`
`32.
`
`For example, during the prosecution of the '720 Patent at the Patent and Trademark
`
`Office, Ravgen explained that the innovative concept of using agents that inhibit cell lysis during
`
`cell-free DNA detection and analysis is recited by the claimed methods of the '720 Patent,
`
`including in claim 1:
`
`Applicant has discovered that the addition of a cell lysis inhibitor to
`a sample prior to detecting the presence of free nucleic acid can
`significantly and unepectedIy increase the proportion of free
`nucleic acid obtained from the non-cellular fraction of a sample.
`
`***
`
`The methods disclosed in claims 1-8, 21-23, and 26 serve a long-felt
`need in the medical community, and provide unexpected results, and
`are therefore non-obvious.
`
`(Ex. 5 ('720 File History, June 2, 2009 Response to Office Action) at 12, 14 (emphasis added).)
`
`33.
`
`The inventive concept of the Patents-in-Suit of including an agent that inhibits cell
`
`lysis—for example, a membrane stabilizer, a cross-linker, and/or a cell lysis inhibitor—with a
`
`sample represented a significant improvement in the preparation of samples used for non-invasive
`
`testing, including non-invasive prenatal testing to unmask previously undetectable fetal genetic
`
`traits. At the time of the invention, it would not have been routine or conventional to add an agent
`
`that inhibits cell lysis to a sample to increase the proportion of free nucleic acid obtained from the
`
`non-cellular fraction of a sample. In fact, as described above, that inventive concept was
`
`10
`
`Ex. 2183, Page 10
`
`

`

`Case 1:20-cv-01730-UNA Document 1 Filed 12/21/20 Page 11 of 27 PagelD #: 11
`
`recognized by Dr. Dhallan's peers as "an important step in improving detection of cell-free DNA."
`
`(Ex. 14 at 1137.)
`
`34.
`
`The '277 Patent is further directed to an unconventional, non-routine method of
`
`detecting fetal chromosomal abnormalities which involves "quantitating a ratio of the relative
`
`amount of alleles in a mixture of maternal DNA and fetal DNA." (Ex. 6 ('277 File History, May
`
`30, 2007 Response to Office Action) at 30.) For example, claim 1 of the '277 Patent recites:
`
`A method for detecting the presence or absence of a fetal
`chromosomal abnormality, said method comprising: quantitating a
`ratio of the relative amounts of alleles at a heterozygous locus of
`interest in a mixture of template DNA, wherein said mixture
`comprises maternal DNA and fetal DNA, and wherein said mixture
`of maternal DNA and fetal DNA has been obtained from a sample
`from a pregnant female, and further wherein said heterozygous locus
`of interest has been identified by determining the sequence of alleles
`at the locus of interest, and wherein said ratio indicates the presence
`or absence of a fetal chromosomal abnormality.
`
`35.
`
`The '277 Patent explains that this claimed method represented a significant
`
`improvement over prior art methods of detecting fetal chromosomal abnormalities, many of which
`
`were costly, time-consuming, and burdensome because they either required the amplification of
`
`the entire sequence of a gene, or quantification of the total amount of a particular gene product.
`
`(Ex. 1 at 66:14-20.) By contrast, the claimed "ratio" method of the '277 Patent only requires
`
`sequencing of discrete "loci of interest" (such as "single nucleotide polymorphisms," or "SNPs")
`
`from the collected DNA sample. (Id. at 34:63-35:37 ("In fact, it is an advantage of the invention
`
`that primers that copy an entire gene sequence need not be utilized. .
`
`.
`
`. There is no advantage to
`
`sequencing the entire gene as this can increase cost and delay results. Sequencing only the desired
`
`bases or loci of interest maximizes the overall efficiency of the method because it allows for the
`
`sequence of the maximum number of loci of interest to be determined in the fastest amount of time
`
`and with minimal cost."); id. at 35:28-37.)
`
`11
`
`Ex. 2183, Page 11
`
`

`

`Case 1:20-cv-01730-UNA Document 1 Filed 12/21/20 Page 12 of 27 PagelD #: 12
`
`36.
`
`During the prosecution of the '277 Patent at the Patent and Trademark Office,
`
`Ravgen gave the following example of an implementation of the claimed "ratio" method:
`
`Applicants have invented a method for detecting the presence or
`absence of a fetal chromosomal abnormality, wherein the method
`comprises, inter alia, quantitating a ratio of the relative amount of
`alleles in a mixture of maternal DNA and fetal DNA.
`
`***
`
`[R]atios were calculated at both chromosomes 13 and 21 in a
`heterogeneous mixture of 75% Down syndrome DNA and 25%
`maternal DNA. Single nucleotide polymorphisms were analyzed
`wherein the maternal genome was homozygous for one allele at a
`specific genetic site and the Down syndrome DNA was
`heterozygous at the same genetic site. If at a certain site, the
`maternal genome contains an adenine at both copies of chromosome
`13, and the Down syndrome genome is comprised of one
`chromosome with an adenine nucleotide and one chromosome with
`a guanine nucleotide, then the ratio of G:A is 0.60 (0.75 (Down
`syndrome G allele)/(0.75 Down syndrome A allele + 0.25 + 0.25
`maternal A alleles).
`
`On the other hand, if at a certain genetic site on chromosome 21, the
`maternal genome contains an adenine at both copies of chromosome
`21, and the Down syndrome genome is comprised of two
`chromosome with an adenine nucleotide and one chromosome with
`a guanine nucleotide, then the ratio of G:A is 0.375 (0.75 (Down
`syndrome G allele)/(0.75 Down syndrome A allele + 0.75 Down
`syndrome A allele + 0.25 + 0.25 (maternal A alleles). Thus, the
`methods described in the present application detect chromosomal
`abnormalities using a method that comprises, inter alia, quantitating
`a ratio of alleles in a heterogeneous mixture of DNA, wherein the
`ratio represents alleles from more than one individual.
`
`(Ex. 6 at 30.)
`
`DEFENDANTS' INFRINGING ACTIVITIES
`
`37.
`
`Ravgen incorporates by reference paragraphs 1-36.
`
`A.
`
`The Accused Myriad Prenatal Screens
`
`38.
`
`In or around September 2014, Counsyl, Inc. ("Counsyl") began offering a
`
`commercial non-invasive prenatal test for detecting fetal chromosomal abnormalities. (See Ex. 20
`
`12
`
`Ex. 2183, Page 12
`
`

`

`Case 1:20-cv-01730-UNA Document 1 Filed 12/21/20 Page 13 of 27 PagelD #: 13
`
`at 5 (https ://blog.myriadwomenshealth.com/20 17/10/24/a-decade-of-counsyl/).) On information
`
`and belief, that non-invasive prenatal test was the "Informed Pregnancy Screen." In 2017, Counsyl
`
`renamed the Informed Pregnancy Screen product to "Prelude Prenatal Screen." (See Ex. 21
`
`(https ://www.businesswire .com/news/home/20 17071900543 8/en/Counsyl-Unveils-Updated-
`
`Names-for-its-Portfolio-of-Genetic-Testing-Products-and-Services);
`
`Ex.
`
`22
`
`(https://blog.myriadwomenshealth.com/2017/06/28/newnames/).)
`
`39.
`
`On or around July 31, 2018, Myriad acquired Counsyl and merged Counsyl with
`
`Myriad
`
`Preventative
`
`Care
`
`to
`
`form
`
`MWH.
`
`(See
`
`Ex.
`
`23
`
`(https://blog.myriadwomenshealth.com/2018/09/1 0/counsyl-transitioning-to-myriad-womens-
`
`health-inc/).) Since Myriad's acquisition of Counsyl, the Prelude Prenatal Screen has been
`
`renamed to "Prequel Prenatal Screen." (Ex. 24 at 1 (https://myriadwomenshealth.com/wp-
`
`content/uploads/2020/06/Prequel-Sample-Report-Trisomy-2 1-Positive-Oil 9 .pdf) ("The Counsyl
`
`Prelude TM Prenatal screen has been renamed the Myriad PrequelTM Prenatal screen."); Ex. 25 at
`
`2658 (Katherine Johansen Taber, et al., Inaccuracies and shortcomings in "Adherence (f cell-free
`
`DNA noninvasive prenatal screens to ACMG recommendations ", 21 GENETICS IN MEDICINE 2658,
`
`2658 (2019)) ("We cite three examples regarding Prelude (now Prequel, Myriad Women's Health
`
`[MWH]). ..
`
`40.
`
`On information and belief, Myriad has offered the Prequel Prenatal Screen since at
`
`least February 11, 2019.
`
`(Ex. 26 (https ://investor.myriad.com!news-releases/news-release-
`
`details/myriad-announces-prequeltm-prenatal-screen-expanded-aneuploidy).)
`
`41.
`
`On information and belief, the "Informed Pregnancy Screen," the "Prelude Prenatal
`
`Screen," and the "Prequel Prenatal Screen" (collectively, the "Myriad Prenatal Screens") at least
`
`require the same methods of sample collection, preparation, and processing to detect fetal
`
`13
`
`Ex. 2183, Page 13
`
`

`

`Case 1:20-cv-01730-UNA Document 1 Filed 12/21/20 Page 14 of 27 PagelD #: 14
`
`chromosomal abnormalities. The Myriad Prenatal Screens have been offered by Defendants since
`
`at least September 2014.
`
`42.
`
`The Myriad Prenatal Screens are "noninvasive prenatal screen[s] that use[] cell-
`
`free DNA (cfDNA) to determine if a pregnancy is at an increased risk for common chromosome
`
`abnormalities, such as Down syndrome." (Ex. 11 at 3 (https://myriadwomenshealth.com/provider-
`
`prequel/).) The Myriad Prenatal Screens require a sample of maternal blood.
`
`(Ex. 27
`
`(https://myriadwomenshealth.com/patient-prequel/) ("All we need is a simple blood draw from
`
`your arm. .
`
`.
`
`43.
`
`The Myriad Prenatal Screens require samples containing an agent that inhibits cell
`
`lysis. For example, MWH's website instructs medical professionals to use a "Streck tube" as the
`
`container for the test specimen requirements. (Ex. 28 (https:Hmyriadwomenshealth.com/how-to-
`
`10ml-blood/).); see also Ex. 29 (https://help.myriadwomenshealth.com/s/article/000016237)
`
`(Question: "How are samples collected for the Prequel PrenatalTM Screen?" Answer: "A sample is
`
`collected from a pregnant patient who is at least 10 weeks . . . into her pregnancy. .. . Specifically,
`
`Myriad Women's Health requires one 1OmL Streck tube. .. .").) Myriad's requisition form for
`
`the Myriad Prenatal Screens instructs to "[u]se (One) 10mL STRECK."
`
`(Ex. 30
`
`(Preconception/Prenatal Requisition Form); see also Ex. 24 (Sample Report) ("Sample Type:
`
`Streck Cell-Free DNA Blood Tube").) On information and belief, "Streck tube" refers to the
`
`Streck Cell-Free DNA Blood Collection Tube ("BCT").
`
`44.
`
`The Streck Cell-Free DNA BCT includes an agent that inhibits cell lysis. A Streck
`
`Cell-Free DNA BCT "stabilizes nucleated blood cells. The unique preservative limits the release
`
`fgenomic D]\A, allowing isolation cf high-quality cell-free D]'iA. Cell-Free DNA BCT has
`
`also been demonstrated to minimize the degradation of circulating tumor cells (CTCs). By limiting
`
`14
`
`Ex. 2183, Page 14
`
`

`

`Case 1:20-cv-01730-UNA Document 1 Filed 12/21/20 Page 15 of 27 PagelD #: 15
`
`cell lysis, the specialized chemistry provides sample integrity during storage, shipping and
`
`handling of blood samples. Cell-free DNA and gDNA are stable for up to 14 days at 6 °C to 37
`
`°C.
`
`CTCs are stable for up to 7 days at 15 °C to 30 °C."
`
`(Ex. 31 at 2
`
`(https ://www.streck.com/products/stabilization/cell-free-dna-bct/#resources).)
`
`45.
`
`In processing the Myriad Prenatal Screens, Defendants isolate cell-free DNA from
`
`a sample of maternal blood collected in a Streck Cell-Free DNA BCT and then analyze the isolated
`
`fetal cfDNA to detect chromosomal abnormalities as shown in Defendants' product documentation
`
`and a number of Myriad-funded scientific studies. The Myriad Prenatal Screens are a
`
`"Noninvasive Prenatal Screening" ("NIPS") that analyzes cell-free DNA using a "whole genome
`
`sequencing" ("WGS") approach.
`
`Introduction
`
`Noninvasive Prenatal Screening (NIPS) via cell-free
`DNA analysis (cfDNA) has been rapidly incorporated
`into prenatal care since it became clinically available
`in 2011. The Myriad Prequel Prenatal Screen TM
`utilizes a whole genome sequencing (WGS) approach
`to NIPS without a fetal fraction cutoff. While various
`laboratories have reported upon a WGS approach to
`NIPS, 12 here we describe the clinical experience in
`our laboratory.
`
`(Ex.
`
`32
`
`(https ://s3 .amazonaws .com/static .counsyl.comi'website/PDFs/posters/ 12 .+Avoiding+Unnecessar
`
`y+Trade-Offs+Clinical+Experience+for+a+Noninvasive+Prenatal+Screen.pdf) ("All authors are
`
`employees of Myriad Genetics.").) "NIPS directly interrogates cfDNA extracted from maternal
`
`plasma . . . ." (Ex. 33 at 334 (Dale Muzzey, et al., Noninvasive prenatal screening for patients
`
`with high body mass index. Evaluating the impact f a customized whole genome sequencing
`
`won flow on sensitivity and residual risk, 40 PRENATAL DIAGNOSTICS 333, 334 (2020).) The
`
`15
`
`Ex. 2183, Page 15
`
`

`

`Case 1:20-cv-01730-UNA Document 1 Filed 12/21/20 Page 16 of 27 PagelD #: 16
`
`Myriad Prenatal Screens then analyze the extracted cfDNA to screen for fetal aneuploidy of
`
`chromosomes
`
`at
`
`MWH's
`
`laboratory.
`
`(Id.;
`
`Ex.
`
`32
`
`(https ://s3 .amazonaws .com/static .counsyl.com!website/PDFs/posters/ 12 .+Avoiding+Unnecessar
`
`y+Trade-Offs+Clinical+Experience+for+a+Noninvasive+Prenatal+Screen.pdf) ("Chromosome
`
`analysis results were reported as no aneuploidy detected ("negative"), aneuploidy detected
`
`("positive"),
`
`or
`
`aneuploidy
`
`suspected
`
`(also
`
`"positive");
`
`Ex.
`
`34
`
`(https:Hmyriadwomenshealth.com/prenatal-virtual-ordering/) ("For Prequel, the patient will
`
`contact Client Services to discuss blood collection options and the phlebotomist will send the
`
`specimen to Myriad for processing.").)
`
`B.
`
`Defendants' Know1ede Of The Raven Patents
`
`46.
`
`The Patents-in-Suit claim advancements in the gen